tbuckley/cabot-search huggingface dataset:
Glucagon, Glucose, and Insulin
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hemorrhagic Stroke
Authors: Sharon Parmet
Journal: JAMA (2004)

Hemorrhagic StrokeA hemorrhagic stroke occurs when a blood vessel in the brain leaks or ruptures, resulting in bleeding into the brain.Parts of the brain affected by the bleeding can become damaged, and if enough blood accumulates, it can put pressure on the brain.The amount of hemorrhage (bleeding) determines the severity of the stroke.The other main type of stroke is caused by blockage in the blood vessels supplying blood to the brain and is called an ischemic stroke.The term ischemia means inadequate blood flow, and stroke refers to the sudden onset of the symptoms.The October 20, 2004, issue of JAMA includes an article about detecting hemorrhagic strokes.
Oxyhemoglobin equilibrium in ischemic heart disease
Authors: M. A. Nevins
Journal: JAMA (1974)

The equilibrium of oxygen and hemoglobin is under multifactorial control. Shifts of oxyhemoglobin dissociation curves have been observed in patients with heart disease. Whether such changes, measurable in vitro, merely represent compensatory mechanisms or play a contributory role in the pathogenesis of ischemia is still uncertain. With the development of newer techniques, the actual rate of oxygen release from hemoglobin can be measured, and this may prove to be a more valid measurement of physiologic oxygen release. Pharmacologic manipulation of oxyhemoglobin equilibrium can be accomplished with various agents, notably propranolol hydrochloride, acetazolamide, and infusion of inosine, phosphorus, and pyruvate. The clinical significance of these effects has not been established, but ultimately they may prove to be useful in improving tissue oxygenation in ischemic conditions. (<i>JAMA</i>229:804-808, 1974)
BMA in Holland.
Journal: BMJ (1977)

God made the world, but the Dutch made Holland; and the threatening sea still pounds at the sand dunes only a mile away from the Leeuwenhorst Congress Centre.This former Jesuit seminary in the tulip fields outside the old university city of Leiden made a fine setting for the Joint Clinical Meeting of the Royal Netherlands Medical Association and the BMA; but sadly much of the time strong winds and showers made sightseeing a blustery business. Close tiesDutch and British doctors have close ties and much in com- mon, said Professor C L C van Nieuwenhuizen in his opening address.In both countries the medical profession found the governmental authorities claiming more and more say in the organisation and content of health care-and, indeed, the Dutch were being threatened with new authoritarian legislation.Dr H W A Sanders, president of the RNMA, explained that in 1976 two draft bills had been published-without consultation with thi official representatives of the medical profession-that proposed far-reaching controls over fees and the organisation of medical practice.In the view of the RNMA the law should concern itself only with the anatomy of health care, leaving the medical profession to control its physiology.The government might stimulate or even supervise, but only rarely should it actually interfere.Nevertheless, said Professor van Nieuwen- huizen, threats to medicine were not confined to those from bureaucrats.There was an internal threat from technological developments such as computer diagnosis-and, as a reaction to that trend, an invasion of the "soft" sciences of sociology and psychology.In an era of change, doctors-and indeed everyone -had to beware of extremes.Too progressive an attitude could be as damaging as an excess of traditionalism. Aspects of Dutch medicineThe first afternoon was spent giving the British visitors a broad picture of Dutch medicine.Dutch health care is based on
News
Journal: BMJ (1989)

Guy's management out of step with consultants At a "pretty stormy" meeting of the Guy's medical and dental committee on 9 May consultants won an assurance from Dr Hugh Saxton, chairman of Guy's Hospital Manage- ment Board, that they would be balloted before any decision about Guy's becoming self governing was taken.This may not seem a very noteworthy concession.As made clear in Self-governing Hospitals (the first working paper issued with Working for Patients), "senior professional staff, especially consultants, must be involved in the management of the [self governing] hospital" (5.1) and "any success- ful proposal would need to demonstrate that it carried the substantial commitment of those likely to be involved in the new man- agement" (5.2).In the context of recent events at Guy's, however, Dr Saxton's con- cession is being hailed as a victory.Guy's Hospital is the flagship of the re- appeared in the Guardian.)
News
Journal: British Journal of Sports Medicine (1990)

from the very efficient and comprehensive medical coverage of sport in East Germany to Belgium whose representative accepted that it was a hobby in his country.The UK was not represented, and your correspondent seemed to be the only UK participant present, despite the current interest in this country in training doctors in sports medicine, and in the setting up a National Sports Medicine Institute.One of the delegates suggested that training in sports medicine should take four years in order to give it credibility, while others suggested a year.The usual and unoriginal com- ment that it should be included in the training of medical students was duly made but roused no response at all.Could it be that more people are realizing that the curriculum is already overcrowded?
Abstract 594: Selective Inhibition Of Lipoprotein-associated Phospholipase A <sub>2</sub> Attenuates Markers Of Plaque Vulnerability In Humans
Authors: Yi Shi, Andrew Zalewski, Colin Macphee, Michelle Dawson
Journal: Circulation (2007)

Background: Lp-PLA 2 , an emerging marker of CV risk, generates products of oxidized LDL that may contribute to inflammation and apoptosis. Although Lp-PLA 2 is highly expressed in thin-cap fibroatheroma and ruptured plaques, its role in mediating lesion vulnerability remains unknown. Material and Methods: Patients were randomized to receive placebo or the selective Lp-PLA 2 inhibitor, darapladib, (40 or 80 mg po) for 14 days prior to carotid endartherectomy. In the post hoc analysis, caspase activities were measured in carotid plaques (colorimetric assays: AU/mg of protein) and correlated with inhibition of Lp-PLA 2 activity in plasma (radiometric assay) using Spearman’s rank method. Results: Caspase-8 (initiator) and -3 (effector) activities were measured as the index of apoptosis in carotid atheroma specimens. In the validation study, carotid atheroma (n=10) exhibited augmented levels of caspase activities compared to non-diseased vessels (n=8) (caspase-8: 4.74±0.3 vs 2.59±0.2; caspase-3: 10.2±0.9 vs 4.15±0.4 p&lt;0.001). Next, caspase-8 (n=39) and -3 (n=59) were measured in plaque samples derived from the dose-ranging study with darapladib. In patients treated with darapladib, caspase-8 activity within the plaques was significantly reduced [placebo: 4.66±0.48; 40 mg: 3.4±0.4, NS; 80 mg: 3.0±0.52, p=0.042 versus placebo (ANOVA with Bonferroni adjustment)]. Similarly, downstream caspase-3 was also decreased in the high dose group (placebo: 11.8±0.84; 40 mg: 10.4±0.88, NS; 80 mg: 6.5±1.0 p=0.0004 versus placebo). To further explore the relationship between Lp-PLA 2 activity and markers of apoptosis, plaque caspase activity was correlated with Lp-PLA 2 inhibition in plasma. Plaque caspase-8 and -3 correlated with inhibition of Lp-PLA 2 activity in plasma (caspase-8: r=-0.34, p=0.039; caspase-3: r=−0.51, p&lt;0.0001). Conclusions: Inhibition of Lp-PLA 2 reduced activity of proapoptotic caspases in human atheroma. The results suggest that Lp-PLA 2 inhibition may attenuate noxious effects of oxidized LDL and promote lesion stabilization in high risk patients.
The Yale Affiliated Gastroenterology Program. University and community hospital cooperation in the training of medical specialists
Authors: R. S. Rosson
Journal: JAMA (1970)

The Yale Affiliated Gastroenterology Program has established clinical traineeships in gastroenterology in six Connecticut community hospitals. Utilizing existing health resources and personnel, the program has increased the output of gastroenterologists in Connecticut threefold from 4 to 12 per year. The gastroenterological trainees at the community hospitals provide mutually advantageous communications between the university medical center and the community hospital health personnel. Resultant improvement in patient care is suggested by increased utilization of gastroenterological consultations and diagnostic procedures in the participating hospitals.
DR. JOHN CONTEE FAIRFAX.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 921: High-throughput functional evaluation of variants of unknown significance inERBB2
Authors: Masaaki Nagano, Shinji Kohsaka, Toshihide Ueno, Shinya Kojima, Masachika Ikegami, Ikuko Takeda, Hiroyuki Mano
Journal: Cancer Research (2018)

Abstract Erb-b2 receptor tyrosine kinase 2 (ERBB2) gene amplification is present in a wide variety of human cancers. ERBB2-targeted therapies have been developed and improved the outcome in patients with ERBB2-positive cancers. Recently, the advent of next-generation sequencing technology has enabled to identify numerous ERBB2 somatic mutations across a variety of cancers, but many of the mutations are still variants of unknown significance (VUS) that await further investigation of clinical relevance. In addition, the sensitivities of those ERBB2 mutations to ERBB2-targeted drugs have not been evaluated systematically. Here we assessed comprehensively the transforming activities as well as drug sensitivities of ERBB2 mutations in a high-throughput manner using the mixed-all-nominated-in-one (MANO) method. We evaluated 55 non-synonymous ERBB2 mutations which are reported recurrently in COSMIC database, and discovered several novel activating mutations which probably drive tumorigenesis. Furthermore, ERBB2 mutations showed varying drug sensitivities to ERBB2-targeted inhibitors. Thus, the MANO method may be a novel approach for assessing VUS, and our findings in this study will be beneficial to deliver personalized medicine to cancer patients harboring ERBB2 mutations. Citation Format: Masaaki Nagano, Shinji Kohsaka, Toshihide Ueno, Shinya Kojima, Masachika Ikegami, Ikuko Takeda, Hiroyuki Mano. High-throughput functional evaluation of variants of unknown significance in ERBB2 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 921.
Regulation of a Graft-Versus-Leukemia Effect by Major Histocompatibility Complex Class II Molecules on Leukemia Cells: HLA-DR1 Expression Renders K562 Cell Tumors Resistant to Adoptively Transferred Lymphocytes in Severe Combined Immunodeficiency Mice/Nonobese Diabetic Mice
Authors: Frank F. Weichold, Yin-zheng Jiang, Daniel E. Dunn, Michael Bloom, Vera Malkovska, Nancy F. Hensel, A. John Barrett
Journal: Blood (1997)
Influenza Vaccine Virus Strains Chosen
Authors: C. Marwick
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
History of the Great War Based on Official Documents. Medical Services: General History. Vol. III. Medical Services During the Operations on the Western Front in 1916, 1917 and 1918; in Italy; and in Egypt and Palestine.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Applying New Biotechnologies to the Study of Occupational Cancer ? A Workshop Summary
Authors: Mark Toraason, Richard Albertini, Steven Bayard, William Bigbee, Aaron Blair, Paolo Boffetta, Stefano Bonassi, Steven Chanock, David Christiani, David Eastmond, Samuel Hanash, Carol Henry, Fred Kadlubar, Frank Mirer, Daniel Nebert, Stephen Rapport, Kathleen Rest, Nathaniel Rothman, Avima Ruder, Russell Savage, Paul Schulte, Jack Siemiatycki, Peter Shields, Martyn Smith, Paige Tolbert, Roel Vermeulen, Paolo Vineis, Sholom Wacholder, Elizabeth Ward, Michael Waters, Ainsley Weston
Journal: Environmental Health Perspectives (2004)
Editor's Note:
Journal: JNCI Journal of the National Cancer Institute (2008)

László Tabár, a coauthor of the Swedish Two-County Trial, has objected to a statement by Carolina Hinestrosa of the National Breast Cancer Coalition Fund claiming that Dr. Tabár has not made the data from the study available for independent review "in the 22 years since the original paper was published."He maintains that he and his colleagues have shared complete, primary raw data with the Independent End-Point Committee of the Swedish Cancer Society that audited the results of the Two-County trial.Dr. Tabár states that some of these results have been published (1-5).Ms. Hinestrosa is also quoted as follows: "NBCCF has been asking for the release of the individual patient data since at least 2002."According to Dr. Tabár, these data have long been on file with the End-Point
Neurological deficits following the hot bath test in multiple sclerosis
Authors: F. A. Davis
Journal: JAMA (1985)

<h3>In Reply.—</h3> We appreciate the comments of Dr Davis concerning our article. We agree that deficits observed in patients with MS might simply reflect a magnification of an acute exacerbation by the hyperthermia with incomplete resolution. This possibility does not negate the mechanisms previously discussed.<sup>1-4</sup>We wish to emphasize that at the time of hot bath testing, our patients were either free of objective evidence of neurological disease (case 1) or had new neurological symptoms for two weeks or longer (cases 2, 3, and 4). In none was the diagnosis of MS initially clear-cut. The frequency with which we see exacerbations following environmental heat exposure, as compared with Northern centers, impresses us that heat itself is a factor. In recent months, we have seen several additional patients experiencing prolonged neurological sequelae following exposure to high environmental temperature. Of these additional patients, five interesting exampies are described. Three of these
THE EXPERIMENTAL PRODUCTION OF CANCER
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Do emergency tests help in the management of acute medical admissions?
Authors: G. Sandler
Journal: BMJ (1984)

dstress Metabolic ackiosis Hyperpyrexia Hyperglycoeamia R if nmpicin Bright red skin pigmentation Red discoloumtion d plasma and urine Liver damage Ethambutol Nausea Abdominal pain Fever Mental confusion Visual hallucinations Optic neuropathyCompound cough mixtures and cold remedies may contain a variety of opioids, antihistamines, and sympathomimetic and mucolytic agents.The management of opioid and antihistamine overdose is covered elsewhere.The various sympathomimetic agents cause acute behavioural disturbances including visual and auditory hallucinations as well as features of cc and i overactivity.These may require specific treatment in the form of sedation or sympathomimetic blocking agents, or both.Chronic use of these drugs may cause behavioural disorders and hallucinations which remit on withdrawal of the drug.Anticholinergic drugs-Agents such as ipratropium bromide are being used increasingly in the treatment of asthma.When administered by inhalation these have a wide safety margin, but accidental or deliberate self-poisoning with nebuliser fluid may cause pronounced anticholinergic poisoning.There have been a few reports of paradoxical bronchoconstriction after both aerosol or high dose nebulised anticholinergic compounds.The reaction to the aerosol is thought to be an allergic response, but the reaction to the nebulised solution may be due to inhalation of a non-isotonic solution.Corticosteroids are occasionally taken in acute overdose but toxic effects are unlikely.Sodium cromoglycate is of low toxicity and overdose needs no specific
Reply:
Authors: Heiner Wedemeyer, Johannes Wiegand, Markus Cornberg, Michael Manns
Journal: Hepatology (2006)

We thank De Rosa and colleagues for their comments highlighting that timing of treatment and compliance are major issues in the treatment of acute hepatitis C. We fully agree that treatment of IVDUs with acute hepatitis C is difficult and that earlier treatment may have advantages in certain settings. However, some centers have reported different experiences in the treatment of acute hepatitis C in IVDUs. The results reported from Italy1 are not in line with experiences in Switzerland showing that barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C.2 We have to stress that patients with ongoing drug abuse were excluded from our study.3 Nevertheless, our experiences in patients with previous drug abuse are also more in line with the Swiss data than with the study by de Rosa et al. demonstrating the importance of thorough patient selection and close monitoring during therapy in the treatment of acute hepatitis C. Optimal timing and duration of treatment in acute hepatitis has been discussed controversially for several years.4 In the Italian study treatment was initiated within 34 days (range: 7-116) of the ALT level peak.1 Considering that the ALT peak occurs usually 4 to 8 weeks after infection, the start of therapy was not different from our study (76 days after infection, range: 14-150 days). We are currently comparing early treatment and delayed treatment in a prospectitve randomized multicenter trial in the German Hep-Net.5 Before this study answering the question on optimal timing of treatment of acute hepatitis C is completed, we would recommend to make decisions on an individual patient basis considering factors such as HCV genotype, severity of symptoms, patients compliance and HCV-RNA kinetics.4 Heiner Wedemeyer*, Johannes Wiegand*, Markus Cornberg*, Michael Manns*, * Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.